Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, Ontario, Canada M5S 3M2.
Pediatrics. 2011 Apr;127(4):e940-7. doi: 10.1542/peds.2010-2914. Epub 2011 Mar 14.
To determine the relative effectiveness of liposomal lidocaine, sucrose, and their combination for reducing pain in term newborns.
Ours was a double-blind, randomized, controlled, double-dummy trial of 330 healthy term newborns. Before venipuncture for the newborn screening test, neonates received (1) 1 g of liposomal lidocaine cream topically, (2) 2 mL of 24% sucrose solution orally, or (3) sucrose and liposomal lidocaine. The facial grimacing score (0-100) was used to assess pain. Adverse events and lidocaine levels were used to assess safety.
Infant characteristics did not differ among groups. Facial grimacing scores were lower in the sucrose group compared with those in the liposomal lidocaine group (mean difference: -27 [95% confidence interval (CI): -36 to -19; P < .001) and for the sucrose plus liposomal lidocaine group compared with those in the liposomal lidocaine group (mean difference: -23 [95% CI: -31 to -14]; P < .001). The sucrose and sucrose plus liposomal lidocaine groups did not differ (mean difference: -5 [95% CI: -13 to 4]; P = .3). Local skin reactions were not observed, and the incidence of spitting up did not differ between sucrose-exposed and non-sucrose-exposed infants (1.4% vs 2.7%, respectively; P = .22). The mean (SD) plasma lidocaine level was 44.6 (55.3) ng/mL.
Sucrose was more effective than liposomal lidocaine for reducing pain during venipuncture in newborns. The addition of liposomal lidocaine to sucrose did not confer any additional benefit to sucrose alone. There was no evidence of harm from liposomal lidocaine or sucrose.
确定脂质体利多卡因、蔗糖及其联合应用在减轻足月新生儿疼痛方面的相对效果。
我们进行了一项 330 例健康足月新生儿的双盲、随机、对照、双模拟试验。在新生儿筛查试验进行前,新生儿接受以下处理:(1)局部使用 1 g 脂质体利多卡因乳膏,(2)口服 2 mL 24%蔗糖溶液,或(3)蔗糖和脂质体利多卡因。采用面部扭曲评分(0-100)评估疼痛。不良事件和利多卡因水平用于评估安全性。
各组婴儿的特征无差异。与脂质体利多卡因组相比,蔗糖组的面部扭曲评分较低(平均差异:-27 [95%置信区间(CI):-36 至-19;P <.001),与蔗糖加脂质体利多卡因组相比,也较低(平均差异:-23 [95% CI:-31 至-14];P <.001)。蔗糖组和蔗糖加脂质体利多卡因组之间没有差异(平均差异:-5 [95% CI:-13 至 4];P =.3)。未观察到局部皮肤反应,且暴露于蔗糖的婴儿与未暴露于蔗糖的婴儿发生呕吐的发生率无差异(分别为 1.4%和 2.7%;P =.22)。平均(标准差)血浆利多卡因水平为 44.6(55.3)ng/mL。
与脂质体利多卡因相比,蔗糖在减轻新生儿静脉穿刺时的疼痛方面更有效。在蔗糖中加入脂质体利多卡因并没有给单独使用蔗糖带来任何额外的好处。脂质体利多卡因或蔗糖均未显示出有害作用。